
Release date: 2026-01-13 17:11:02 Article From: Lucius Laos Recommended: 117
Capivasertib (trade name: Truqap) is the world’s first approved AKT protein kinase inhibitor. Combined with fulvestrant, it is indicated for the treatment of hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with specific gene mutations (PIK3CA/AKT1/PTEN).
The dosage of this medicine may vary among different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. Do not change your dose unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. In addition, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Adults: 400 mg twice a day (with an interval of at least 12 hours between two doses), administered continuously for 4 days followed by a 3-day drug holiday per week. Your doctor may adjust the dosage based on your needs and tolerance.
Children: The usage and dosage must be determined by a doctor.
Get emergency medical help or call emergency services (e.g., 911) immediately if you experience any of the following severe side effects:
Severe headache, confusion, slurred speech, weakness of arms or legs, difficulty walking, loss of coordination, unsteadiness, abnormally stiff muscles, high fever, profuse sweating or tremors.
Severe eye symptoms such as sudden vision loss, blurred vision, narrowed visual fields (tunnel vision), eye pain or swelling, or seeing halos around lights.
Severe cardiac symptoms including rapid, irregular or pounding heartbeat; fluttering sensation in the chest; shortness of breath; sudden dizziness, lightheadedness or fainting.
1. Storage conditions: Store in the original package at room temperature. If removed from the original packaging, any unused portion should be discarded after 45 days.
2. Environmental requirements: Store in a dry place. Do not store in the bathroom.
3. Safe storage: Keep all medicines in a safe place, out of the reach of children and pets.
4. Disposal: Discard any unused or expired medicine. Do not flush down the toilet or pour into a drain unless instructed to do so. Consult your pharmacist if you have questions about the best way to dispose of your medication. There may be drug take-back programs in your area.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: